Fig. 2: ELISpot analysis of tumor-associated antigens. | Prostate Cancer and Prostatic Diseases

Fig. 2: ELISpot analysis of tumor-associated antigens.

From: Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

Fig. 2: ELISpot analysis of tumor-associated antigens.

ELISpot analyses are shown for all 7 patients (A–G) who had evaluable samples. Error bars represent the standard deviation of 3 replicates for each ELISpot. C = cycle; CEFT = cytomegalovirus, Epstein-Barr virus, influenza, and tetanus toxoid; D = day; LLO = listeriolysin O; PAP = prostatic acid phosphatase; PBMC = peripheral blood mononuclear cell; PSMA = prostate-specific membrane antigen; SCR = screening; SFC = spot forming colonies; SSX-2 = synovial sarcoma X chromosome breakpoint-2.

Back to article page